参芪十一味颗粒联合EOX方案化疗治疗晚期胃癌27例

目的:比较参芪十一味颗粒联合EOX方案与单纯EOX方案治疗晚期胃癌的疗效及毒副反应。方法:将经病理学或细胞学和影像学确诊为晚期胃癌患者作为研究对象,均有可客观测量的病灶,分为参芪十一味颗粒联合EOX方案组(参芪组)33例及单纯EOX方案组(对照组)27例。每例患者至少接受治疗2周期以上。结果:参芪组27例部分缓解(PR)12例,稳定(SD)9例,总有效率为44.4%;对照组27例获PR 11例,SD 8例,总有效率为40.7%;两组疗效比较无显著性差异(P>0.05)。参芪组白细胞减少的发生率、III-IV度胃肠道反应和肝肾毒性显著少于对照组(P<0.05)。参芪组生活质量Karnofsky评分提高率58%,对照组提高率30%,两组差异有显著性(P<0.05)。结论:参芪十一味颗粒能够减少EOX方案化疗毒副作用,增加患者化疗耐受性,提高生活质量。

Compound shenqishiyiweikeli combined with EOX chemotherapy in the treatment of 27 patients with advanced gastric carcinoma

Objective： To observe and compare the efficacies and toxicities of compound shenqishiyiweikeli combined with EOX regimen （ Epirubicin ＋ Oxaliplatin ＋ Capecitabine） and EOX regimen alone in the treatment of patients with advanced gastric carcinoma. Methods：Patients with advanced gastric carcinoma, diagnosed by histopathology, cytology and imaging, were divided into 2 groups. They were treated with EOX regimen alone （control group, n = 25 ） or combination with compound shenqishiyiweikeli （ shenqishiyiwei group, n = 25 ）. Each pationts received at least 2 cycles of the treatments. Results ： In shenqishiyiwei group, the overall response rate was 44.4% （ PR in 12 patients, SD in 9 patients, and PD in 6 patients）. In control group, the overall response rates was 40.7% （PR in 11 patients, SD in 8 patients, and PD in 8 patients）. The difference in the overall response rates between the two groups was insignificant （ P 〉 0.05 ）. The increase rate of Karnofsky score for the quality of life （58.0%） in shenqishiyiwei group was significantly higher than that （30%） in control group （P 〈 0.05 ）. The incidence rates of leucopenia, grade Ⅲ - Ⅳ gastrointestinal reations, hepatotoxicity reactions, hepatotoxicity and renal toxicity in shenqishiyiwei group were significantly lower than those in control group（ P 〈 0. 05 ）. Conclusion：Compound shenqishiyiweikeli can attenuate toxic effects of EOX chemotherapy,enhance patients＂ tolerance to chemotherapy and improve patients＇ quality of life.